Contineum Therapeutics Overview
Latest P/E ratio for Contineum Therapeutics: -8.95 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-8.95
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for CTNM is -8.95. That is below the sector sector average of 44.85. Investors often review this figure alongside Contineum Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, CTNM currently prints -8.95 for P/E ratio, while the sector average sits near 44.85. That is roughly 120.0% below the sector mean. Large gaps often invite a closer look at Contineum Therapeutics's growth, margins, and balance sheet.
A P/E ratio of -8.95 for Contineum Therapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (44.85) and with CTNM's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting CTNM's P/E ratio (-8.95), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
